Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430297 | 1.00 | TRPV1 (0.41) | TRPV1PNMTCA2ADRA2AADRA2B | |
| SCHEMBL3322149 | 0.84 | PNMT (0.46) | TRPV1PNMT | |
| SCHEMBL3322142 | 0.84 | PNMT (0.46) | TRPV1PNMT | |
| SCHEMBL10593024 | 0.83 | TRPV1 (0.37) | TRPV1 | |
| SCHEMBL31316850 | 0.78 | ADRA2A (0.50) | ADRA2AADRA2BADRA1A | |
| SCHEMBL14275635 | 0.78 | ADRA2A (0.50) | ADRA2AADRA2BADRA1A | |
| SCHEMBL23976381 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA1AADRA2C | |
| SCHEMBL1265342 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA1A | |
| SCHEMBL1265344 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA1A | |
| SCHEMBL1266132 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885PNMT 1462/4885CA2 369/4885 |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | TRPV1, MRGPRX1, MRGPRX4 | TRPV1 1/4885PNMT 1821/4885CA2 554/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885PNMT 1565/4885CA2 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.